Travere Therapeutics
TVTX
113 hedge funds and large institutions have $1.03B invested in Travere Therapeutics in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 11 closing their positions.
682% more call options, than puts
Call options by funds: $13.3M | Put options by funds: $1.7M
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
30% more capital invested
Capital invested by funds: $792M → $1.03B (+$236M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
5% more funds holding
Funds holding: 108 → 113 (+5)
0.56% more ownership
Funds ownership: 106.98% → 107.54% (+0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$23.5M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$15.1M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$5.95M |
| 4 |
Millennium Management
New York
|
+$5.73M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$25.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11M |
| 3 |
Jennison Associates
New York
|
-$6.66M |
| 4 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$6.24M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$4.84M |
TVTX Hedge Fund Activity: Q3 2017 in Review
113 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2017, worth a combined $1.03B — up 30% from $792M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TVTX positions and 11 closed out — a net gain of 6 holders — while 46 added to existing stakes and 29 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $23.5M. The largest seller was Broadfin Capital, cutting an estimated $25.2M.
- 113 institutional investors held Travere Therapeutics (TVTX) as of Q3 2017, up from 108 in Q2 2017.
- Funds reported $1.03B of Travere Therapeutics stock for Q3 2017, up 30% quarter-over-quarter.
- 17 funds opened new Travere Therapeutics positions in Q3 2017 and 11 closed out, a net change of +6 holders.
- The largest Travere Therapeutics buyer in Q3 2017 was Consonance Capital Management, an estimated $23.5M added.
- The largest Travere Therapeutics seller in Q3 2017 was Broadfin Capital, an estimated $25.2M sold.
Based on aggregated 13F filings for Q3 2017.